scholarly journals Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early-Stage Non-small Cell Lung Cancer

2009 ◽  
Vol 4 (7) ◽  
pp. 891-910 ◽  
Author(s):  
Ana Belén Custodio ◽  
José Luis González-Larriba ◽  
Jana Bobokova ◽  
Antonio Calles ◽  
Rafael Álvarez ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Predictive Markers ◽  
Small Cell Lung ◽  
Prognostic And Predictive Markers

scholarly journals Trial on Refinement of Early stage non-small cell lung cancer. Adjuvant chemotherapy with pemetrexed and cisplatin versus vinorelbine and cisplatin: The TREAT protocol

BMC Cancer ◽  
2007 ◽  
Vol 7 (1) ◽  
Author(s):  
Michael Kreuter ◽  
Johan Vansteenkiste ◽  
Frank Griesinger ◽  
Hans Hoffmann ◽  
Hendrik Dienemann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Clinically relevant prognostic and predictive markers for immune-checkpoint-inhibitor (ICI) therapy in non-small cell lung cancer (NSCLC)

BMC Cancer ◽  
2020 ◽  
Vol 20 (1) ◽  
Author(s):  
Wolfgang M. Brueckl ◽  
Joachim H. Ficker ◽  
Gloria Zeitler
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Genetic Markers ◽  
Cell Lung Cancer ◽  
Immune Checkpoint ◽  
Palliative Treatment ◽  
Small Cell ◽  
Predictive Markers ◽  
Small Cell Lung ◽  
Prognostic And Predictive Markers

Abstract Background Immune checkpoint inhibitors (ICI) either alone or in combination with chemotherapy have expanded our choice of agents for the palliative treatment of non-small cell lung cancer (NSCLC) patients. Unfortunately, not all patients will experience favorable response to treatment with ICI and may even suffer from severe side effects. Therefore, prognostic and predictive markers, beyond programmed death ligand 1 (PD-L1) expression status, are of utmost importance for decision making in the palliative treatment. This review focuses on clinical, laboratory and genetic markers, most of them easily to obtain in the daily clinical practice. Results Recently, a number of prognostic and predictive factors in association to palliative ICI therapy have been described in NSCLC. Besides biometric parameters and clinical characteristics of the tumor, there are useful markers from routine blood sampling as well as innovative soluble genetic markers which can be determined before and during ICI treatment. Additionally, the level of evidence is noted. Conclusions These factors can be helpful to predict patients’ outcome and tumor response to ICI. They should be implemented prospectively in ICI based clinical trials to develop reliable algorithms for palliative NSCLC treatment.

Adjuvant chemotherapy following SBRT for early stage non-small cell lung cancer (NSCLC) in older patients

2020 ◽  
Vol 11 (7) ◽  
pp. 1145-1153
Author(s):  
Madison Grinnell ◽  
Adams Kusi Appiah ◽  
Michael Baine ◽  
Vinicius Ernani ◽  
Alissa Marr ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adjuvant Chemotherapy ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Older Patients ◽  
Early Stage ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Tumor Endothelial Markers (TEMS) as Prognostic and Predictive Markers in Non-Small Cell Lung Cancer (NSCLC)

2012 ◽  
Vol 23 ◽  
pp. ix76
Author(s):  
A. Pircher ◽  
G. Untergasser ◽  
I.M. Heidegger ◽  
J. Kern ◽  
E. Gunsilius ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Predictive Markers ◽  
Small Cell Lung ◽  
Endothelial Markers ◽  
Prognostic And Predictive Markers
Sign in / Sign up

Export Citation Format

Share Document